HORIZON EUROPE: HEALTH CLUSTER

Dr. Horváth Klára

Agenda

• HE overview
• Health cluster
• Work Programme 2021-2022
• Partnerships
• Cancer Mission
• ERA-NET calls
• Q and A
HORIZONE EUROPE

THREE PILLARS FOR IMPLEMENTATION

Pillar 1: EXCELLENT SCIENCE
- European Research Council
- Marie Skłodowska-Curie Actions
- Research Infrastructures

Pillar 2: GLOBAL CHALLENGES & EUROPEAN INDUSTRIAL COMPETITIVENESS
- Health
- Culture, Creativity and Inclusive Society
- Civil Security for Society
- Digital, Industry and Space
- Climate, Energy and Mobility
- Food, Bioeconomy, Natural Resources, Agriculture and Environment
- Joint Research Centre

Pillar 3: INNOVATIVE EUROPE
- European Innovation Council
- European innovation ecosystems
- European Institute of Innovation and Technology

WIDENING PARTICIPATION AND STRENGTHENING THE EUROPEAN RESEARCH AREA
- Widening participation and spreading excellence
- Reforming and Enhancing the European R&I system

+ Partnerships
- Cancer Mission
- EIT Health KIC
- (Emergency WP?)
Budget

Horizon Europe: Total budget: **95.5 Billion Euros**
Tackling climate change: **35%**

HE Cluster Health: **8.246 Billion Euros**
10%: Cancer Mission
Max. 50%: Partnerships

EU4Health Programme: **5.1 Billion Euros**
Health Cluster

Challenges:

• a complex, evolving demography (ageing, multi-morbidities, …)

• achieving greater resilience and equity in our healthcare systems;

• the need to be better prepared for the accelerating pace of change and possible shocks to our societies.
Role of Research & Innovation:

• advance knowledge and capabilities,
• improve understanding of health and diseases,
• develop innovative methodological and technological solutions to better manage health and diseases,
• design sustainable approaches for the digital transformation and delivery of integrated, person-centred and equitable health and care services.
Health Cluster

• **Policy framework: documents:**
  - Sustainable Development Goals
  - EU Recovery plan
  - EU Health Union
  - European Green Deal
  - Europe fit to the Digital Age
  - Farm to Fork Strategy
  - Pharmaceutical Strategy for Europe
  - European One Health Action Plan
  - Chemical Strategy for Sustainability
Health Cluster

• Impact
• Interdisciplinary, cross-sectoral
• Social Sciences and Humanities (SSH)
• Co-design; Multi-actor approach: end-users, patients, patients organizations, regulatory bodies
• Open science
• Gender aspects
• Closed/running projects
• Joint actions with the other winning projects
Type of action

- **Research and Innovation Action (RIA)**
  - Funding rate: 100%
- **Innovation Action (IA)**
  - Funding rate: 70% (non-profit organisations: 100%)
- **Coordination and Support Action (CSA)**
  - Funding rate: 100%
- Pre-Commercial Procurement (PCP);
- Public Procurement of Innovative Solutions (PPI)
- Co-Fund Partnership
- Indirect cost: 25%
Rules of participation

• **Rules of participation:** Any legal entity, regardless of its place of establishment, including legal entities from nonassociated third countries or international organisations may participate in actions.

• **Funding:** member states + associated countries + USA

• Entities shall be part of a consortium that shall include at least three independent legal entities each established in a different Member State or associated country and with at least one of them established in a Member State (Exception: Coordination and Support Actions may be implemented by one or more legal entities, plus specific rules for Procurement Actions).
Health Cluster

Structure of the 2-year Work Programmes:

- Introduction
  - Destination
    - Call/year
      - Topics:
        - Title
        - Specific Conditions related to topic (budget, type of action)
        - Expected outcome: what should be achieved from the project
        - Scope: what should be done in the project

Timeline: Call opening: 22 April 2021   First deadlines: September 2021
Destinations

Six “Destinations”:

• 1. **Staying healthy** in a rapidly changing society
• 2. Living and working in a health-promoting **environment**
• 3. **Tackling diseases** & reducing disease burden
• 4. Ensuring access to innovative, sustainable & high-quality **Healthcare**
• 5. Unlocking the full potential of **new tools, technologies and digital solutions** for a healthy society
• 6. Maintaining an innovative, sustainable & globally **competitive health industry**
Staying healthy in a rapidly changing society

- R&I should provide new evidence, methodologies and tools to understand the transition from health to disease, preventing diseases and promoting health.

Expected impacts:

- the promotion of healthier lifestyles, behaviours and environments to enable citizens stay healthy throughout the life; Innovative evidence-based services, policies and guidelines for health promotion and disease prevention;
- accessible, equitable and effective co-designed digital solutions for promoting health and preventing disease;
- collaborations across sectors and with other HE clusters to transform the healthcare system from reacting to illness, to proactively promoting health and preventing disease.
<table>
<thead>
<tr>
<th>Topic title</th>
<th>Type of Action</th>
<th>Single stage/Two stage</th>
<th>Budget (Million EUR)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Towards a molecular and neurobiological understanding of mental health and mental illness for the benefit of citizens and patients</td>
<td>RIA</td>
<td>Single stage</td>
<td>60.00 (10.00/project)</td>
</tr>
<tr>
<td>Supporting digital empowerment and health literacy – Healthy citizens 2.0</td>
<td>CSA</td>
<td>Single stage</td>
<td>3.00</td>
</tr>
<tr>
<td>A roadmap for personalised prevention</td>
<td>CSA</td>
<td>Single stage</td>
<td>3.00</td>
</tr>
<tr>
<td>Mobilising the network of National Contact Points in the Health Cluster</td>
<td>CSA</td>
<td>Single stage</td>
<td>3.00</td>
</tr>
<tr>
<td>Topic title</td>
<td>Type of Action</td>
<td>Single stage/ Two stage</td>
<td>Budget (Million EUR)</td>
</tr>
<tr>
<td>----------------------------------------------------------------------------</td>
<td>----------------</td>
<td>-------------------------</td>
<td>-------------------------------</td>
</tr>
<tr>
<td>Boosting mental Health in Europe in times of change</td>
<td>RIA</td>
<td>Two stage</td>
<td>50.00 (7.00/project)</td>
</tr>
<tr>
<td>Trustworthy AI tools to predict the risk of chronic non-communicable diseases and/or their progression</td>
<td>RIA</td>
<td>Two stage</td>
<td>60.00 (6.00/project)</td>
</tr>
<tr>
<td>Prevention of obesity through the life course</td>
<td>RIA</td>
<td>Two stage</td>
<td>60.00 (10.00/project)</td>
</tr>
<tr>
<td>Personalised blue print of chronic inflammation in health-to-disease transition</td>
<td>RIA</td>
<td>Single stage</td>
<td>50.00 (7.00/project)</td>
</tr>
</tbody>
</table>
Living and working in a health-promoting environment

• The environment we live and work in has direct or indirect beneficial or adverse impacts on human health and well-being. It is a major determinant of health and well-being.

Expected impacts:

• the knowledge to identify and assess the risks and benefits for health of living and working environments to enable the design of health-promoting and disease preventive policy actions and dissemination of best practices;

• solid scientific evidence and uptake of research results into relevant environmental, occupational, social, economic, fiscal and health policies at EU, national and regional level;

• new/improved health interventions, technologies, tools and services for care and health.
## CALL TOPICS 2021

<table>
<thead>
<tr>
<th>Topic title</th>
<th>Type of Action</th>
<th>Single stage/Two stage</th>
<th>Budget (Million EUR)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exposure to electromagnetic fields (EMF) and health</td>
<td>RIA</td>
<td>Single stage</td>
<td>30.00 (8.00/project)</td>
</tr>
<tr>
<td>Indoor air quality and health</td>
<td>RIA</td>
<td>Single stage</td>
<td>40.00 (8.00/project)</td>
</tr>
<tr>
<td>Health impacts of climate change, costs and benefits of action and inaction</td>
<td>RIA</td>
<td>Single stage</td>
<td>60.00 (10.00/project)</td>
</tr>
<tr>
<td><em>European Partnership for the Assessment of Risks from Chemicals (PARC)</em></td>
<td><em>Co-Fund Partnership</em></td>
<td><em>Single stage</em></td>
<td>200.00</td>
</tr>
<tr>
<td>Topic title</td>
<td>Type of Action</td>
<td>Single stage/Two stage</td>
<td>Budget (Million EUR)</td>
</tr>
<tr>
<td>----------------------------------------------------------------------------</td>
<td>----------------</td>
<td>------------------------</td>
<td>----------------------</td>
</tr>
<tr>
<td>Methods for assessing health-related costs to environmental stressors</td>
<td>RIA</td>
<td>Single stage</td>
<td>20.00 (4.00/project)</td>
</tr>
</tbody>
</table>
Tackling diseases & reducing disease burden

Expected impacts:

- For health burden of diseases in the EU and worldwide to be reduced through effective disease management, including through the development and integration of innovative diagnostic and therapeutic approaches, personalised medicine approaches, digital and other people-centred solutions for health and care.

- Patients should be diagnosed early and accurately and receive effective, cost-efficient and affordable treatment, including for rare diseases.

- Premature mortality from non-communicable diseases reduced by one third by 2030.

- Health care systems should be better prepared to respond to health emergencies.

- Patients and citizens should be knowledgeable of disease threats, involved and empowered to make and shape decisions for their health.
<table>
<thead>
<tr>
<th>Topic title</th>
<th>Type of Action</th>
<th>Single stage/ Two stage</th>
<th>Budget (Million EUR)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Towards improved supportive, palliative, survivorship and end-of-life care</td>
<td>RIA Single stage</td>
<td>Single stage</td>
<td>50.00 (6.00/project)</td>
</tr>
<tr>
<td>of cancer patients</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Building a European innovation platform for the repurposing of medicinal</td>
<td>RIA Single stage</td>
<td>Single stage</td>
<td>50.00 (25.00/project)</td>
</tr>
<tr>
<td>products</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Innovative approaches to enhance poverty-related diseases research in</td>
<td>RIA Single stage</td>
<td>Single stage</td>
<td>40.00 (8.00/project)</td>
</tr>
<tr>
<td>sub-Saharan Africa</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical validation of artificial intelligence solutions for treatment and</td>
<td>RIA Single stage</td>
<td>Single stage</td>
<td>60.00 (6.00/project)</td>
</tr>
<tr>
<td>care</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Topic title</td>
<td>Type of Action</td>
<td>Single stage/Two stage</td>
<td>Budget (Million EUR)</td>
</tr>
<tr>
<td>----------------------------------------------------------------------------</td>
<td>----------------</td>
<td>------------------------</td>
<td>----------------------</td>
</tr>
<tr>
<td>Personalised medicine and infectious diseases: understanding the individual host response to viruses (e.g., SARS-CoV-2)</td>
<td>RIA</td>
<td>Single stage</td>
<td>60.00 (7.00/project)</td>
</tr>
<tr>
<td>A roadmap towards the creation of the European One Health antimicrobial resistance partnership (OH AMR)</td>
<td>CSA</td>
<td>Single stage</td>
<td>0.5</td>
</tr>
<tr>
<td>Building a European Research and Innovation Partnership for Pandemic Preparedness</td>
<td>CSA</td>
<td>Single stage</td>
<td>2.00</td>
</tr>
<tr>
<td>Topic title</td>
<td>Type of Action</td>
<td>Single stage/ Two stage</td>
<td>Budget (Million EUR)</td>
</tr>
<tr>
<td>----------------------------------------------------------------------------</td>
<td>----------------</td>
<td>-------------------------</td>
<td>----------------------</td>
</tr>
<tr>
<td>Pre-clinical development of the next generation immunotherapies for diseases or disorders with unmet medical need</td>
<td>RIA</td>
<td>Two stage</td>
<td>60.00 (6.00/project)</td>
</tr>
<tr>
<td>Vaccines 2.0 - developing the next generation of vaccines</td>
<td>RIA</td>
<td>Two stage</td>
<td>40.00 (8.00/project)</td>
</tr>
<tr>
<td>Development of new effective therapies for rare diseases</td>
<td>RIA</td>
<td>Two stage</td>
<td>60.00 (8.00/project)</td>
</tr>
<tr>
<td>Pandemic Preparedness - Placeholder</td>
<td>RIA</td>
<td>Single stage</td>
<td>10.00</td>
</tr>
</tbody>
</table>
## CALL TOPICS 2022

<table>
<thead>
<tr>
<th>Topic title</th>
<th>Type of Action</th>
<th>Single stage/ Two stage</th>
<th>Budget (Million EUR)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-communicable diseases risk reduction in adolescence and youth</td>
<td>RIA</td>
<td>Single stage</td>
<td>25.00 (3.00/project)</td>
</tr>
<tr>
<td>GloPID R secretariat - Placeholder</td>
<td>CSA</td>
<td>Single stage</td>
<td>2.00</td>
</tr>
<tr>
<td>European Partnership Fostering an ERA for Health research</td>
<td>Co-Fund Partnership</td>
<td>Single stage</td>
<td>30.00</td>
</tr>
</tbody>
</table>
Ensuring access to innovative, sustainable & high quality Healthcare

Expected impacts:

• Health and social care services and systems that have improved governance and are more effective, efficient, accessible, resilient, trusted and sustainable, with health promotion and disease prevention at their heart.

• Health care providers that are trained and equipped with the skills and competences suited for the future needs of health care systems.

• People enabled to play a key role in managing their own health and care and specific needs of more vulnerable groups are recognised and addressed.

• People can also benefit from improved access to health care services, including safe, effective, and affordable essential medicines and vaccines.
# CALL TOPICS 2021

<table>
<thead>
<tr>
<th>Topic title</th>
<th>Type of Action</th>
<th>Single stage/Two stage</th>
<th>Budget (Million EUR)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Enhancing quality of care and patient safety</td>
<td>RIA</td>
<td>Single stage</td>
<td>25.00 (5.00/project)</td>
</tr>
<tr>
<td>Data-driven decision-support tools for better health and care delivery and policy-making</td>
<td>RIA</td>
<td>Single stage</td>
<td>40.00 (4.00/project)</td>
</tr>
<tr>
<td>Health and care innovation procurement network</td>
<td>CSA</td>
<td>Single stage</td>
<td>5.00</td>
</tr>
</tbody>
</table>
# CALL TOPICS 2022

<table>
<thead>
<tr>
<th>Topic title</th>
<th>Type of Action</th>
<th>Single stage/Two stage</th>
<th>Budget (Million EUR)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Innovation procurement (PCP) for building the resilience of health and care systems in the context of recovery</strong></td>
<td>PCP</td>
<td>Single stage</td>
<td>25.00 (5.00/project)</td>
</tr>
<tr>
<td><strong>Innovation procurement (PPI) for building the resilience of health and care systems in the context of recovery</strong></td>
<td>PPI</td>
<td>Single stage</td>
<td>15.00 (5.00/project)</td>
</tr>
<tr>
<td><strong>Better economic foresight, financial planning and procurement/contractual strategies for health systems</strong></td>
<td>RIA</td>
<td>Single stage</td>
<td>30.00 (5.00/project)</td>
</tr>
<tr>
<td><strong>European Partnership on Transforming Health and Care Systems</strong></td>
<td>Co-Fund Partnership</td>
<td>Single stage</td>
<td>100.00</td>
</tr>
</tbody>
</table>
Destination 5
Unlocking the full potential of new tools, technologies and digital solutions for a healthy society

Expected impacts:

• contribute to Europe’s scientific and technological expertise and know-how, its capabilities for innovation in **new tools, technologies and digital solutions**, and its ability to take-up, scale-up and integrate innovation in health and care;

• **enable researchers, innovators and health care providers** to use health data and **AI supported decision-making** in a secure and ethical, acceptable and trustworthy manner.

• citizens should benefit from targeted and faster research resulting in safer, more efficient, cost-effective and affordable tools, technologies and **digital solutions for effective personalised disease prevention, diagnosis, treatment and monitoring for better patient outcome** and well-being, in particular through increasingly shared health resources.
## CALL TOPICS 2021

<table>
<thead>
<tr>
<th>Topic title</th>
<th>Type of Action</th>
<th>Single stage/ Two stage</th>
<th>Budget (Million EUR)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smart medical devices and their surgical implantation for use in resource- constrained settings</td>
<td>IA</td>
<td>Single stage</td>
<td>25.00 (6.00/project)</td>
</tr>
<tr>
<td>Next generation advanced therapies to treat highly prevalent and high burden diseases with unmet needs</td>
<td>RIA</td>
<td>Single stage</td>
<td>60.00 (6.00/project)</td>
</tr>
<tr>
<td>Innovative tools for use and re-use of health data (in particular electronic health records and/or patient registries)</td>
<td>RIA</td>
<td>Single stage</td>
<td>30.00 (8.00/project)</td>
</tr>
</tbody>
</table>
## CALL TOPICS 2022

<table>
<thead>
<tr>
<th>Topic title</th>
<th>Type of Action</th>
<th>Single stage/ Two stage</th>
<th>Budget (Million EUR)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Optimising effectiveness in patients of existing prescription drugs for major diseases (except cancer) with the use of biomarkers</td>
<td>RIA</td>
<td>Single stage</td>
<td>60 (10/project)</td>
</tr>
<tr>
<td>New methods for the effective use of real-world data and/or synthetic data in regulatory decision-making and/or in health technology assessment</td>
<td>RIA</td>
<td>Single stage</td>
<td>35 (7/project)</td>
</tr>
<tr>
<td>Computational models for new patient stratification strategies</td>
<td>RIA</td>
<td>Two stage</td>
<td>60 (6/project)</td>
</tr>
</tbody>
</table>
Destination 6

Maintaining an innovative, sustainable & globally competitive health industry

Expected impacts:

• **Health industry** should be more competitive, sustainable and growing, providing high value jobs and contributing to economic growth, in particular SMEs, by tapping into new markets and providing European leadership in health technologies and innovations.

• Citizens, health care providers and health systems should benefit from swift uptake of innovative health technologies and services offering significant improvements.

• Health industry should work more efficiently along the value chain from the identification of needs to the scale-up and take-up of solutions at national, regional or local level, including through early engagement with all stakeholders to ensure suitability and acceptance of solutions.
### CALL TOPICS 2021

<table>
<thead>
<tr>
<th>Topic title</th>
<th>Type of Action</th>
<th>Single stage/Two stage</th>
<th>Budget (Million EUR)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Green pharmaceuticals</td>
<td>RIA</td>
<td>Single stage</td>
<td>40 (8/project)</td>
</tr>
<tr>
<td>Development procurement and responsible management of new antimicrobials</td>
<td>CSA</td>
<td>Single stage</td>
<td>2</td>
</tr>
<tr>
<td>Promoting a trusted mHealth label in Europe: uptake of Technical specifications for “Quality and Reliability of Health and Wellness Apps”</td>
<td>CSA</td>
<td>Single stage</td>
<td>2</td>
</tr>
<tr>
<td>Topic title</td>
<td>Type of Action</td>
<td>Single stage/Two stage</td>
<td>Budget (Million EUR)</td>
</tr>
<tr>
<td>----------------------------------------------------------------------------</td>
<td>----------------</td>
<td>------------------------</td>
<td>----------------------</td>
</tr>
<tr>
<td>Enhancing Cybersecurity of connected Medical Devices</td>
<td>RIA</td>
<td>Single stage</td>
<td>20 (6/project)</td>
</tr>
<tr>
<td>Scaling up multi-party computation, data anonymisation techniques and synthetic data generation</td>
<td>RIA</td>
<td>Single stage</td>
<td>30 (7/project)</td>
</tr>
<tr>
<td>New payment models for cost-effective and affordable health innovations/new models of pricing</td>
<td>RIA</td>
<td>Single stage</td>
<td>15 (5/project)</td>
</tr>
<tr>
<td>Setting up a European Smart Health Innovation Hub</td>
<td>CSA</td>
<td>Single stage</td>
<td>2</td>
</tr>
<tr>
<td>Setting up a European Electronic Health Record Exchange Format Ecosystem</td>
<td>CSA</td>
<td>Single stage</td>
<td>2</td>
</tr>
</tbody>
</table>
Partnerships

- to rationalise the European R&I partnerships landscape
- to improve the openness and transparency of R&I partnerships
- to link the R&I partnerships to future EU R&I missions and/or strategic priorities
Partnerships

• EU-Africa Global Health Partnership
• Innovative Health Initiative
• European Partnership for Chemicals Risk Assessment (PARC)
• ERA for Health Research
• Health and Care Systems Transformation
• Personalised Medicine
• Rare Diseases
• One Health/AMR
• (Preparedness and Brain Health)

Partnerships

- **Innovative Medicines Initiative (IMI)**
- Public-Private Partnership (PPP)
- Industry partner: EFPIA
- 2 stage calls
- Call topics: EFPIA

- **Innovative Health Initiative (IHI)**
- PPP
- Industry partner: EFPIA, COCIR, EuropaBio, MedTech Europe, Vaccines Europe
- 1 stage and 2 stage calls
- Innovation panel
Partnerships

**ERA for Health Research**

- Based on H2020 ERA-NETs and other programmes: Cancer, CVD, Systems Medicine, NanoMedicine, JPI HDHL, etc.
- Preclinical research
- Future: Clinical research?

**European Partnership for Chemicals Risk Assessment (PARC)**

- Based on Human Biomonitoring EJP
- PARC is an EU-wide research and innovation programme to support EU and national chemical risk assessment
- Hu partner: Országos Környezetegészségügyi Intézet
EIT Health KIC

• Established in 2015, EIT Health is focused on answering some of Europe’s biggest health challenges; bringing together over 1,000 partners

• Programmes:

• **Accelerator:** Catalyses new business growth to deliver transformative products and services. The Health KIC works with entrepreneurs, start-ups and SMEs to **shorten the time-to-market for life-changing products and services.**

• **Campus:** Bridges the gap between academia and enterprise to **upskill professionals** on new innovative techniques

• **Innovation:** we build a task force of world-class experts from the worlds of business, research and education to **develop the most promising solutions into real-world commercially-viable products or services.**

• [https://eithealth.eu/](https://eithealth.eu/)
Missions

• “Missions provide a solution, an opportunity, and an approach to address the numerous challenges that people face in their daily lives”
  Professor Mariana Mazzucato

• Connecting to citizens: Missions will relate EU's research and innovation to society and citizens' needs, with strong visibility and impact to rationalise the European R&I partnerships landscape.

• A mission will consist of a portfolio of actions intended to achieve a bold and inspirational as well as measurable goal within a set timeframe, with impact for science and technology, society and citizens that goes beyond individual actions.
Missions

- **Prepare Europe for climate disruptions and accelerate the transformation to a climate resilient and just Europe**

- **Mission starfish 2030:** Restore our ocean waters

- **By 2030 more than 3 million lives saved, living longer and better**

- **By 2030 at least 75% of all soils in each EU Member State are healthy**

- **100 Climate-neutral cities by 2030**
Cancer Mission

- Europe has a **25% all cancer cases** and less than **10 % of the world’s population**.
- Each year, **2.6 million people** in the EU-27 are **diagnosed** with cancer.
- Without strong action, the number of cancer cases in Europe will increase **by 25 % by 2035**.
- Cancer **kills 1.2 million** people in the EU-27 each year.
- Hungary: 2020 incidence: 5th in Europe  
  mortality: 2nd in Europe

**Target:** By 2030 more than 3 million lives saved, living longer and better
Cancer Mission

• Prevention
• Early detection
• Diagnosis and treatment
• Quality of life for patients and survivors

Cancer Mission Board

Cancer Mission

5 intervention areas:

- Understand cancer, its risk factors and impact
- Prevent what is preventable
- Optimise diagnostics and treatment
- Support quality of life
- Ensure equitable access
Cancer Mission

13 recommended actions:
• Launch UNCAN.eu
• Identify (poly-)genic risk scores
• Effective cancer prevention strategies and policies
• Screening and early detection
• Personalised medicine approaches
• Early diagnostics and minimally invasive treatment
• Improve the quality of life of cancer patients and survivors
• Create a European Cancer Patient Digital Centre
• Achieve Cancer Health Equity
• Network of Comprehensive Cancer Infrastructures

• Childhood cancers
• Oncology-focused Living Labs
• Transform cancer culture
<table>
<thead>
<tr>
<th>Topic title</th>
<th>Type of Action</th>
<th>Budget (Budget/project)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preparing <em>UNCAN.eu</em>, a European initiative to understand cancer</td>
<td>CSA</td>
<td>3.00 million EUR</td>
</tr>
<tr>
<td>Procurement actions to support an EU mission on cancer:</td>
<td>Public Procurement</td>
<td>2.00 million EUR</td>
</tr>
<tr>
<td>Prevent the preventable</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Optimise diagnosis and treatment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Quality of life</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
H2020 ERA-NETs

- ERA-PERMED
- JPND
- RARE DISEASES EJP
- NEURON
- JPIAMR
- TRANSCAN

- Smaller consortia
- Up to 3 years
- 2 stage calls
- Easier application
- International evaluation
- Different countries!
- Widening actions

Hu participants: 2019-2.1.7-ERA-NET


- Budget: 300 000 EUR
ERA NET calls 2021

ERA PERMED call 2021:

• „Multidisciplinary research projects on personalised medicine - Development of clinical support tools for personalised medicine implementation”
• Deadline for pre-proposals: 4 March 2021; for full-proposals: 17 June 2021
• https://erapermed.isciii.es/joint-calls/joint-transnational-call-2021/

JPND call 2021:

• "Linking pre-diagnosis disturbances of physiological systems to Neurodegenerative Diseases"
• Deadline for pre-proposals: 2 March 2021; for full-proposals: 29 June 2021
• https://www.neurodegenerationresearch.eu/initiatives/annual-calls-for-proposals/linking-pre-diagnosis-disturbances-of-physiological-systems-to-neurodegenerative-diseases/
NEURON Cofunded call 2021:

• “Call for Proposals for Transnational Research Projects on Neurodevelopmental Disorders”

• Deadline for pre-proposals: 9 March 2021; for full-proposals: 30 June 2021
  

JPIAMR Cofunded call 2021:

• “One Health interventions to prevent or reduce the development and transmission of AMR”

• Deadline for pre-proposals: 16 March 2021; for full-proposals: 12 July 2021
  
ERA-NET calls 2021

TRANSCAN Cofunded call 2021:
• „Next generation cancer immunotherapy: targeting the tumour microenvironment„
• Will be published soon!

RARE DISEASES EJP call 2021:
• Closed

• ERA-NET calls 2022!
Important websites

• Open calls:
  • https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/home

• EU research results:
  • https://cordis.europa.eu/

• EU research and innovation data: Horizon Dashboard
  • https://webgate.ec.europa.eu/dashboard/sense/app/93297a69-09fd-4ef5-889f-b83c4e21d33e/sheet/a879124b-bfc3-493f-93a9-34f0ebfa124/state/analysis

• Register as experts:
  • https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/work-as-an-expert

• NCP:
  • http://www.h2020.gov.hu/horizont2020-program/nemzeti-kapcsolattarto
Köszönöm a figyelmet!

klara.horvath@nkfih.gov.hu